Clinical outcomes for poor prognosis PBTs, such as diffuse midline glioma (DMG)2, including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG),3 atypical teratoid rhabdoid tumor (ATRT),4 and MYC and MYCN-amplified medulloblastoma (MB),5 remain poor. This evidence concerns the gene MYCN and diffuse intrinsic pontine glioma.